A
Amy P. Abernethy
Researcher at Duke University
Publications - 586
Citations - 29463
Amy P. Abernethy is an academic researcher from Duke University. The author has contributed to research in topics: Palliative care & Population. The author has an hindex of 76, co-authored 586 publications receiving 25420 citations. Previous affiliations of Amy P. Abernethy include University of Technology, Sydney & Johns Hopkins University School of Medicine.
Papers
More filters
Journal Article
Chronic refractory dyspnoea--evidence based management.
TL;DR: Evidence that can guide the safe, symptomatic management of chronic refractory dyspnoea is distil from the peer reviewed literature (literature search and guidelines) and is likely within the first 72 hours.
Journal ArticleDOI
Racial differences in pain during 1 year among women with metastatic breast cancer
Liana D. Castel,Benjamin R. Saville,Venita DePuy,Paul A. Godley,Katherine E Hartmann,Amy P. Abernethy +5 more
TL;DR: Information on pain predictors refines the understanding of patients with greatest distress and need, as well as providing insight into the course of pain, across the disease trajectory.
Journal ArticleDOI
Analyzing Phase III Studies in Hospice/Palliative Care. A Solution That Sits Between Intention-to-Treat and Per Protocol Analyses: The Palliative-Modified ITT Analysis
TL;DR: The palliative-modified ITT analysis should be the primary evaluation of hospice/palliative care Phase III studies but, as a minimum, should routinely be the key sensitivity analysis.
Journal ArticleDOI
The Quality Imperative for Palliative Care
Arif H. Kamal,Arif H. Kamal,Laura C. Hanson,David Casarett,Sydney M. Dy,Steven Z. Pantilat,Dale Lupu,Amy P. Abernethy,Amy P. Abernethy +8 more
TL;DR: Palliative medicine must move beyond demonstrating to its constituents, "here is what the authors do," and increase the focus on "this is how well they do it" and "let us see how they can do it better."
Journal ArticleDOI
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
Antoni Ribas,Jason Chesney,Michael S. Gordon,Amy P. Abernethy,Theodore F. Logan,David H. Lawson,Bartosz Chmielowksi,John A. Glaspy,Karl D. Lewis,Bo Huang,Erjian Wang,Poe Hirr Hsyu,Jesus Gomez-Navarro,Jesus Gomez-Navarro,Diana Gerhardt,Margaret A. Marshall,Rene Gonzalez +16 more
TL;DR: This study did not identify any safety concerns when tremelimumab was administered as a 1-hour infusion and the overall side effect profile was consistent with prior experiences with anti-CTLA4 antibodies.